This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wakeland EK et al. (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15: 397–408
Sharif MN et al. (2004) IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 172: 6476–6481
Davidson A et al. (2005) Block and tackle: CTLA4Ig takes on lupus. Lupus 14: 197–203
Schiffer L et al. (2003) Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 171: 489–497
Aringer M et al. (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50: 3161–3169
Theofilopoulos AN et al. (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307–336
Nestle FO et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202: 135–143
Ramanujam M et al. (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116: 724–734
Goodnow CC (2006) Immunology. Discriminating microbe from self suffers a double toll. Science 312: 1606–1608
Lagakos SW (2006) The challenge of subgroup analyses—reporting without distorting. N Engl J Med 354: 1667–1669
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A Davidson is a Consultant for Abbott Pharmaceuticals. She has participated in clinical trials of CTLA4Ig. Dr Davidson has received NIH grant support to study STLA4Ig in murine SLE.
Rights and permissions
About this article
Cite this article
Davidson, A. New immune modulatory drugs for systemic lupus erythematosus—what can we expect?. Nat Rev Rheumatol 2, 638–639 (2006). https://doi.org/10.1038/ncprheum0301
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0301